BMS’ Inrebic (fedratinib) Receives Health Canada’s Approval for Patients with Myelofibrosis

 BMS’ Inrebic (fedratinib) Receives Health Canada’s Approval for Patients with Myelofibrosis

BMS’ Inrebic (fedratinib) Receives Health Canada’s Approval for Patients with Myelofibrosis

Shots: 

  • The approval is based on JAKARTA and JAKARTA2 clinical trials. JAKARTA study involves assessing Inrebic (500mg) vs PBO for at least 6 cycles in 289 patients in patients with intermediate-2 or high-risk MF, post-polycythemia vera MF or post-essential thrombocythemia MF with splenomegaly and platelet count ≥50 x 109/L
  • The P-II JAKARTA 2 study involves assessing of Inrebic (400mg, qd) in 97 patients prior exposed to ruxolitinib with a diagnosis of intermediate-1 with symptoms, intermediate-2 or high-risk MF, post-polycythemia vera MF or post-essential thrombocythemia MF with splenomegaly and platelet count ≥50 x 109/L.1
  • The 1EPs of the studies is ≥35% reduction in the volume of spleen size at the end of Cycle 6. Inrebic is a JAK inhibitor and is the first new treatment for patients with myelofibrosis in nearly a decade

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: BMS

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post